clinical trial · NCT07382739
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
M.D. Anderson Cancer Center·phase2·recruiting·n = 34
Phase 2Radiotherapy-Induced Immune PrimingElranatamabRelapsed Refractory Multiple Myeloma (RRMM)Extramedullary Disease in Multiple MyelomaParamedullary DiseasePMDElranatamab
brief summary
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
started
Mar 31, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2030
last updated
Apr 14, 2026
detailed description
Primary Objectives To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate (ORR) at 3 months
Secondary Objectives To describe adverse events (AEs). To determine time to next treatment (TTNT). To evaluate progression-free survival (PFS). To determine overall survival (OS). To estimate quality of life (QOL). To assess local control to the irradiated lesions To determine differences in response in patients with EMD vs PMD To determine differences in response in patients High Risk (HR) vs Standard Risk (SR) disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol